Targeting the ATR-CHK1 Axis in Cancer Therapy
- PMID: 28448462
- PMCID: PMC5447951
- DOI: 10.3390/cancers9050041
Targeting the ATR-CHK1 Axis in Cancer Therapy
Abstract
Targeting the DNA damage response (DDR) is a new therapeutic approach in cancer that shows great promise for tumour selectivity. Key components of the DDR are the ataxia telangiectasia mutated and Rad3 related (ATR) and checkpoint kinase 1 (CHK1) kinases. This review article describes the role of ATR and its major downstream target, CHK1, in the DDR and why cancer cells are particularly reliant on the ATR-CHK1 pathway, providing the rationale for targeting these kinases, and validation of this hypothesis by genetic manipulation. The recent development of specific inhibitors and preclinical data using these inhibitors not only as chemosensitisers and radiosensitisers but also as single agents to exploit specific pathologies of tumour cells is described. These potent and specific inhibitors have now entered clinical trial and early results are presented.
Keywords: ATR; CHK1; DNA-damage; DNA-repair; cell cycle; chemotherapy-sensitising-agents; protein-kinase-inhibitors; radiation-sensitising-agents.
Conflict of interest statement
Nicola Curtin has received funding from Vertex pharmaceuticals and worked in collaboration with Vernalis on V158411. The other authors declare no conflict of interest.
Figures

Similar articles
-
ATR/CHK1 inhibitors and cancer therapy.Radiother Oncol. 2018 Mar;126(3):450-464. doi: 10.1016/j.radonc.2017.09.043. Epub 2017 Oct 18. Radiother Oncol. 2018. PMID: 29054375 Free PMC article. Review.
-
Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets.Cancers (Basel). 2024 Mar 13;16(6):1139. doi: 10.3390/cancers16061139. Cancers (Basel). 2024. PMID: 38539474 Free PMC article. Review.
-
The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.J Virol. 2018 Feb 26;92(6):e01884-17. doi: 10.1128/JVI.01884-17. Print 2018 Mar 15. J Virol. 2018. PMID: 29263259 Free PMC article.
-
Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.Ultrason Sonochem. 2012 Nov;19(6):1246-51. doi: 10.1016/j.ultsonch.2012.04.003. Epub 2012 Apr 19. Ultrason Sonochem. 2012. PMID: 22571845
-
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.Mol Cell Oncol. 2015 Feb 23;2(4):e1012976. doi: 10.1080/23723556.2015.1012976. eCollection 2015 Oct-Dec. Mol Cell Oncol. 2015. PMID: 27308506 Free PMC article. Review.
Cited by
-
Advancing cancer therapy: new frontiers in targeting DNA damage response.Front Pharmacol. 2024 Sep 20;15:1474337. doi: 10.3389/fphar.2024.1474337. eCollection 2024. Front Pharmacol. 2024. PMID: 39372203 Free PMC article. Review.
-
Caspase activation counteracts interferon signaling after G2 checkpoint abrogation by ATR inhibition in irradiated human cancer cells.Front Oncol. 2022 Oct 28;12:981332. doi: 10.3389/fonc.2022.981332. eCollection 2022. Front Oncol. 2022. PMID: 36387237 Free PMC article.
-
ASPM promotes ATR-CHK1 activation and stabilizes stalled replication forks in response to replication stress.Proc Natl Acad Sci U S A. 2022 Oct 4;119(40):e2203783119. doi: 10.1073/pnas.2203783119. Epub 2022 Sep 26. Proc Natl Acad Sci U S A. 2022. PMID: 36161901 Free PMC article.
-
Metastasis-associated gene 1 (MTA1) enhances cisplatin resistance of malignant pleural mesothelioma by ATR-Chk1-mediated DNA repair.Ann Transl Med. 2021 Apr;9(8):670. doi: 10.21037/atm-21-941. Ann Transl Med. 2021. PMID: 33987368 Free PMC article.
-
HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma.Oncol Rep. 2019 Dec;42(6):2309-2322. doi: 10.3892/or.2019.7343. Epub 2019 Oct 1. Oncol Rep. 2019. PMID: 31578594 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous